SLC7A13

Across TCGA pan-cancer cohorts, SLC7A13 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of SLC7A13’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where SLC7A13 RNA is repressed in tumor relative to normal tissue. In most cancer types SLC7A13 is over-expressed in tumor, although a few such as KIRC and KIRP show the opposite, repressed pattern.

KIRC, KIRP, and KICH are the cancer types where SLC7A13 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC7A13 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	All	−2.750	<.001	12	view →
KIRP	All	IV	−4.745	<.001	11	view →
KICH	All	II,III,IV	−2.834	<.001	7	view →
BRCA	All	II,III,IV	+0.507	<.001	4	view →
LIHC	All	All	+0.053	.030	1	view →
CHOL	All	All	−0.040	.040	1	view →
READ	Female	All	−0.026	.049	1	view →
LUSC	Female	All	+0.009	.032	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

SLC7A13–KIRC

Open the KIRC breakdown →